Recent 8-K filings for NRIX

• April 8, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Nurix Q1 net loss $87.2M ($0.79); advancing bexobrutideg registrational program

  Revenue $6.3M vs $18.5M YoY; net loss $87.2M ($0.79) vs $56.4M ($0.67).

• January 28, 2026, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Nurix reports FY2025 net loss of $264.5M; initiates DAYBreak registrational program for bexobrutideg

  FY2025 revenue $84.0M (+54% YoY); net loss $264.5M ($3.05/sh) vs $193.6M ($2.88/sh) last year.

• January 12, 2026, 6:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Nurix outlines bexobrutideg pivotal CLL plan, 83% ORR, $664M cash at JPM

  Phase 2 DAYBreak CLL-201 enrolled Oct 2025; confirmatory Phase 3 vs pirtobrutinib planned in 2026.

• December 9, 2025, 6:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Nurix releases Phase 1 CLL/SLL data: 83% ORR, 22.1mo PFS; WM ORR 75.0% at ASH 2025

  Phase 1a CLL/SLL ORR 83.0% (47 evaluable), including 4.3% complete responses; median PFS 22.1 months, DOR 20.1 months.

• October 22, 2025, 7:59 PM ET other material materiality 0.75 neutral item 8.01item 9.01

  Nurix raises $250M in registered offering; shares priced at $10.21

  Offering of 24,485,799 shares at $10.21/share; gross proceeds $250.0M, net ~$234.3M.

• October 22, 2025, 7:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Nurix initiates pivotal Phase 2 DAYBreak trial of bexobrutideg in r/r CLL with 600 mg QD dose

  DAYBreak Phase 2 will enroll ~100 r/r CLL/SLL patients after prior cBTKi, ncBTKi, and BCL-2i; primary endpoint is ORR by IRC.

• October 9, 2025, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01

  Nurix Q3 FY2025 net loss $86.4M ($1.03/share); cash $428.8M; bexobrutideg pivotal trials on track

  Revenue $7.9M vs $12.6M YoY; net loss $86.4M ($1.03/sh) vs $49.0M ($0.67/sh) YoY.

• September 3, 2025, 7:59 PM ET other material materiality 0.65 neutral item 7.01item 9.01

  Nurix begins investor meetings with updated clinical plans for bexobrutideg Phase 1 trial

  Company presenting updated development plans for bexobrutideg (NX-5948), an oral BTK degrader.

• July 9, 2025, 7:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Nurix Q2 FY2025 revenue $44.1M (+264% YoY); Sanofi extends STAT6 license; bexobrutideg 80.9% ORR in CLL

  Revenue $44.1M (vs $12.1M YoY) driven by $30M Sanofi license extensions and $5M Gilead milestone.

• June 12, 2025, 7:59 PM ET other material materiality 0.70 positive item 7.01item 8.01item 9.01

  Nurix bexobrutideg shows 80.9% ORR in CLL, 84.2% in WM; pivotal trials on track for 2025

  ORR 80.9% in CLL/SLL (n=47 evaluable); median time to first response 1.9 months; one complete response after >2 years.

• April 8, 2025, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Nurix posts Q1 FY2025 net loss $56.4M; bexobrutideg gets orphan drug designation

  Revenue $18.5M, up from $16.6M YoY; net loss $56.4M ($0.67/share) vs $41.5M prior year.

• January 28, 2025, 6:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01

  Nurix Therapeutics reports FY2024 net loss $193.6M, cash $609.6M; NX-5948 ORR 75.5%

  Revenue of $54.5M in FY2024, down from $77.0M YoY; net loss $193.6M ($2.88/share) vs $143.9M ($2.65) prior year.

• January 13, 2025, 6:59 PM ET other material materiality 0.75 positive item 2.02item 7.01item 9.01

  Nurix reports preliminary cash $609.6M; plans pivotal CLL trials for NX-5948 in 2025

  Preliminary cash and investments $609.6M as of Nov 30, 2024; runway into H1 2027.

• December 10, 2024, 6:59 PM ET other material materiality 0.85 positive item 7.01item 8.01item 9.01

  Nurix: NX-5948 Phase 1 CLL/SLL shows 75.5% ORR, deepens to 84.2%; safe; pivotal trials in 2025

  ORR 75.5% (n=49) in heavily pretreated CLL/SLL; 84.2% in patients with at least 2 assessments.

• October 11, 2024, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Nurix Therapeutics reports Q3 FY2024 net loss $49M, $0.67 per share; cash $457.5M

  Net loss $49.0M ($0.67 per share) vs $37.0M ($0.68 per share) in Q3 FY2023.

• July 11, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 8.01item 9.01

  Nurix posts Q2 net loss $44.5M; cash rises to $452.5M; NX-5948 ORR 69.2% in CLL

  Net loss $44.5M ($0.71/sh) vs $24.3M ($0.45/sh) YoY; collaboration revenue $12.1M (+13% YoY).

• June 17, 2024, 7:59 PM ET other material materiality 0.75 positive item 7.01item 8.01item 9.01

  Nurix Therapeutics: NX-5948 achieves 69.2% ORR in Phase 1 CLL; pivotal trial planned for 2025

  Objective response rate of 69.2% in 26 evaluable CLL patients across 50-600 mg daily doses; responses deepened over time.

• April 12, 2024, 7:59 PM ET other material materiality 0.70 neutral item 1.01item 8.01item 9.01 ◈ Material Agreements

  Nurix prices upsized $175M public offering of 10.17M shares and prefunded warrants at $15.00/share

  10,166,667 common shares at $15.00/share plus 1,500,100 pre-funded warrants at $14.999/warrant.

• April 10, 2024, 7:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01 ◈ Earnings Releases

  Nurix Therapeutics Q1 FY2024 revenue $16.6M, net loss $41.5M; Gilead collaboration extended

  Revenue $16.6M (up 31% YoY); net loss $41.5M ($0.76/sh) vs $40.7M ($0.75/sh) prior year.

• April 9, 2024, 7:59 PM ET other material materiality 0.75 positive item 8.01item 9.01

  Nurix announces first clinical responses in brain for BTK degrader NX-5948

  NX-5948 detected in CSF from all available samples, showing brain penetration.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.85 · Median 0.70 · Most common event other_material

14 positive 0 negative 16 neutral

source · NRIX on sec.gov